Lattice Biologics Ltd.
LBLTF
$0.00
$0.000.00%
OTC PK
| 06/30/2021 | 03/31/2021 | 12/31/2020 | 09/30/2020 | 06/30/2020 | |
|---|---|---|---|---|---|
| Revenue | 1.56M | 2.06M | 2.24M | 2.46M | 2.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.56M | 2.06M | 2.24M | 2.46M | 2.19M |
| Cost of Revenue | 912.40K | 1.26M | 1.20M | 1.28M | 1.44M |
| Gross Profit | 645.70K | 807.10K | 1.04M | 1.18M | 748.50K |
| SG&A Expenses | 794.40K | 1.11M | 1.05M | 1.01M | 1.30M |
| Depreciation & Amortization | 345.20K | 397.00K | 369.60K | 381.00K | 253.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.05M | 2.76M | 2.62M | 2.68M | 3.00M |
| Operating Income | -493.90K | -695.40K | -378.10K | -214.20K | -808.10K |
| Income Before Tax | -923.60K | -1.22M | -1.68M | -1.48M | -1.91M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.92 | -1.22 | -1.68 | -1.48 | -1.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -923.60K | -1.22M | -1.68M | -1.48M | -1.91M |
| EBIT | -493.90K | -695.40K | -378.10K | -214.20K | -808.10K |
| EBITDA | -209.50K | -451.40K | -118.90K | 61.50K | -624.70K |
| EPS Basic | -0.01 | -0.01 | -0.02 | -0.01 | -0.02 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.02 | -0.01 | -0.02 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 508.53M | 479.85M | 445.09M | 410.33M | 379.91M |
| Average Diluted Shares Outstanding | 508.53M | 479.85M | 445.09M | 410.33M | 379.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |